首页 › 急性髓系白血病 › 俄克拉荷马州 › Oklahoma City
Oklahoma City OK 急性髓系白血病临床试验
14项针对 急性髓系白血病的研究正在 Oklahoma City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Mercy Hospital Oklahoma City, Oklahoma City
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- OU Health Stephenson Cancer Center, Oklahoma City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- University of Oklahoma Health Science Center, Oklahoma City
Pilot Imaging Study of Leukemia
招募中1 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- OU Health Stephenson Cancer Center, Oklahoma City
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
其他城市的 急性髓系白血病试验
- Houston, TX85 项研究
- New York City, NY51 项研究
- Boston, MA44 项研究
- Seattle, WA41 项研究
- Baldwin Park, CA40 项研究
- Columbus, OH35 项研究
- Philadelphia, PA34 项研究
- Durham, NC33 项研究
- Atlanta, GA31 项研究
- Tampa, FL29 项研究
- Chicago, IL26 项研究
- Portland, OR25 项研究
Oklahoma City的其他研究
- 非小细胞肺癌28 项研究
- 卵巢癌28 项研究
- 子宫内膜癌25 项研究
- 结直肠癌22 项研究
- 前列腺癌21 项研究
- 肺癌19 项研究
- 乳腺癌17 项研究
- 转移性癌症16 项研究
- 癌症（所有类型）14 项研究
- 头颈鳞状细胞癌13 项研究
- 膀胱癌11 项研究
- 胰腺癌11 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。